Bill, I would welcome 15 or 20 dollars as well. No doubt about it. However, that would still represent a hefty paper loss for those that got in at .25 or higher.
The silver lining that I see is the EUA did not get rejected due to lack of efficacy (which is just what happened to the IPAX drug on Nov 11, 2021). They took an 80% hit, but they failed the clinical trials. We did not fail. The FDA simply wants more trial data before making a hard decision either way. So there is still hope here.
News 
Market Data 
Discover 
